

Network Connectivity Determines Cortical Thinning In Early Parkinson's Disease Progression

Y. Yau*¹, Y. Zeighami*¹, T. Baker², K. Larcher¹, U. Vainik^{1,3}, M. Dadar¹, V. Fonov¹, P. Hagmann⁴, A. Griffa⁵, B. Mišić¹, D.L. Collins¹ & A. Dagher¹

¹ Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, QC, H3A 2B4, Canada

² Center for Molecular and Behavioral Neuroscience, Rutgers University, 197 University Avenue, Newark, NJ, 07102, U.S.A.

³ Institute of Psychology, Faculty of Social Sciences, University of Tartu, Näituse 2, 50409, Tartu, Estonia

⁴ Department of Radiology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 21, 1011 Lausanne, Switzerland

⁵ Brain Center Rudolf Magnus, UMC Utrecht, Heidelberglaan 100, A01.126, 3508 GA Utrecht, Netherlands\

* *These authors contributed equally*

ABSTRACT

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor and cognitive deficits. The neurodegenerative process is thought to move stereotypically from the brainstem up to the cerebral cortex, possibly reflecting the spread of toxic alpha-synuclein molecules. Using a large, longitudinal, multi-center database of *de novo* PD patients, we tested whether focal reductions in cortical thickness could be explained by disease spread from a subcortical “disease reservoir” along the brain’s connectome. PD patients (n=105) and matched controls (n=57) underwent T1-MRI at entry and one year later. Over this period, PD patients demonstrated significantly greater loss of cortical thickness than healthy controls in parts of the left occipital and bilateral frontal lobes and right somatomotor-sensory cortex. Cortical regions with greater connectivity (measured functionally or structurally) to a “disease reservoir” evaluated via MRI at baseline demonstrated greater atrophy one year later. The atrophy pattern in the ventral frontal lobes resembled one described in certain cases of Alzheimer’s disease. Moreover, a multiple linear regression model suggested that cortical thinning was associated with impaired cognitive function at follow-up. Our findings suggest that disease propagation to the cortex in PD follows neural connectivity, and that disease spread to the cortex may herald the onset of cognitive impairment.

INTRODUCTION

The network spread hypothesis proposes that neurodegenerative diseases target intrinsic brain networks. Specifically, it is suggested that the progression of disease follows network connectivity, and that neurodegeneration is caused by the spread and accumulation of toxic agents along the brain's neuronal connectome^{1,2}. In the case of Parkinson's Disease (PD), the likely agent is misfolded α -synuclein (α -syn). In its normal conformation, α -syn is an endogenous protein that is soluble and contributes to synaptic vesicular function³; however, in synucleinopathies such as PD, α -syn is present in a hyperphosphorylated and insoluble state, and found to adopt an abnormal configuration into amyloid fibril aggregates^{4,5}. A model first proposed by Braak suggested that patterns of abnormal α -syn accumulation observed at post-mortem were consistent with a stereotyped propagation from brainstem to subcortical areas to cortex, which paralleled the clinical progression of the disease⁶. Numerous lines of evidence support this model: misfolded α -syn aggregates are identified at postmortem in the brains of PD patients, and the protein has been shown to spread through neuroanatomical pathways and to cause cell death in animal models^{4,5}; however, the model remains controversial and direct human evidence is sparse⁷⁻⁹.

There is currently no imaging technique that allows *in vivo* measurement of α -syn in the brain. However, we previously observed a pattern of brain atrophy in cross sectional MRI scans of *de novo* PD patients from the Parkinson's Progression Markers Initiative (PPMI) database¹⁰ that was consistent with the network spread hypothesis¹¹. The regional distribution of atrophy identified using deformation based morphometry (DBM) overlapped with an intrinsic connectivity network, and the pattern suggested a disease epicenter in the substantia nigra. The

atrophy distribution was mostly subcortical, involving brainstem, striatum, thalamus and medial temporal lobe. Here we make use of the longitudinal data collected at diagnosis and approximately one-year later from the PPMI cohort to test the hypothesis that disease spread from this initial subcortical “disease reservoir” to cortical regions is best explained by propagation via the brain’s intrinsic connectome.

Recent studies using voxel based morphometry (VBM) to assess grey matter density have begun to highlight a pattern of cortical changes in PD^{12,13}, but there have been discrepant findings^{14,15}. Inconsistencies are in-part due to heterogeneity in disease progression and small sample sizes, but also to methodological issues¹⁶. Cortical thickness analysis may be better able to delineate cortical morphometrical patterns and may be more sensitive to age or disease-related regional grey matter changes than VBM^{17,18}. While cortical thinning is normal in the aging process¹⁹, deviations from typical patterns can be used as diagnostic indicators for neurodegenerative disorders (e.g., Alzheimer’s disease) even at early stages²⁰. Several cross-sectional studies of MRI-derived cortical thickness in early stage PD have reported cortical thinning in parietal and premotor regions compared to controls^{18,21-23}. Moreover, cortical thinning appears to correlate with poorer cognitive performance²⁴. However, cortical thickness in PD has yet to be studied in a controlled longitudinal setting and little is known how it may correlate with other disease-related measures.

Disease spread to cortical areas may be accompanied by the start of cognitive impairment. Dementia is now recognized as a common, perhaps inevitable, feature of PD^{25,26}. Cognitive impairment takes several forms, starting with executive (frontal lobe) dysfunction and apathy, and progressing to visual hallucinations, impulse control and behavioral disorders, and,

eventually, a global cognitive impairment that resembles Alzheimer's Disease (AD)²⁶⁻²⁹. As with the classical dementias, it is likely that the specific pattern of disease spread in PD may shape the clinical features of the dementing process¹.

Here we take advantage of follow-up imaging in a large longitudinal, multi-center study that aimed to assess the progression of clinical features, imaging, and other biomarkers in a cohort of well-characterized *de novo* PD patients. Using the PPMI database (<http://www.ppmi-info.org/data>), we test the theory that disease progression at a one-year follow-up, as assessed by cortical thickness, is best explained by spread from a “disease reservoir” along the brain’s connectome. We further ask what factors at baseline predict severity of disease progression at follow-up, and whether cortical involvement might herald the onset of cognitive decline.

RESULTS

Participants

Participants in the present study consisted of *de novo* PD patients ($n=105$) and healthy controls (HC, $n=57$) enrolled in the PPMI study¹⁰ [accessed May 01, 2016, clinicaltrials.gov identifier NCT01141023] who had follow-up assessment one-year post-enrolment (1.05 years for both groups). Demographic and clinical data are summarized in Table 1. PD patients were unmedicated at the first evaluation. At one-year follow-up, 81 of 105 were on PD medication (e.g., levodopa or dopamine agonist). Among PD patients, performance on the Montreal Cognitive Assessment (MoCA) was slightly worse at follow-up compared to baseline (from 27.5 to 26.7, $t(103)=3.038$, $p=.003$). PD patients also scored higher on the Movement Disorders

Society Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) at follow-up compared to baseline, but this did not reach statistical significance (from 21.7 to 23.1, $t(95)=-1.544$, $p=.126$).

Changes in Cortical Thickness at One-Year Follow-Up

Over the one-year period, mean whole-brain cortical thickness significantly decreased amongst both PD patients ($t_1 = 3.055\text{mm}\pm0.013$; $t_2 = 3.027\text{mm}\pm0.013$) and controls ($t_1 = 3.055\text{mm}\pm0.016$; $t_2 = 3.036\text{mm}\pm0.017$) (both $p<0.01$). Regional cortical thinning was greater in PD than HC (Figure 1). Specifically, four significant clusters were identified: (1) left occipital and inferior and middle temporal gyri, (2) left frontal, (3) right frontal, and (4) right pre- and post-central gyrus and supramarginal gyrus (Figure 2). The frontal lobe atrophy mostly involved the inferior parts of lateral and medial frontal cortex, including the orbitofrontal cortex, frontal pole, ventromedial and rostral dorsomedial prefrontal cortex. On the lateral surface inferior and medial frontal gyri were implicated, with extension to the superior frontal gyrus on the left. In order to assess the likely functional consequences of cortical thinning in PD, we assigned each cortical parcel to one of the seven intrinsic brain networks derived from resting state fMRI by Yeo et al.³⁰. Cortical regions belonging to the limbic, frontoparietal, and ventral attention networks on average demonstrated the greatest cortical thinning, as well as anterior parts of the default mode network (Figure 3). There were no areas showing greater loss of cortical thickness in HC than PD.

Connectivity and Disease Propagation

The disease propagation hypothesis predicts that cortical brain atrophy at follow-up should depend on connectivity of cortical areas to affected areas at baseline. We had previously shown

predominant subcortical atrophy in *de novo* PD in this population. Connectivity between any cortical area and this putative subcortical “disease reservoir” should therefore predict the degree of cortical thinning relative to age-matched controls when comparing follow-up to baseline. We define the disease reservoir as the subcortical areas showing atrophy in PD patients relative to controls at the initial evaluation, as determined previously using DBM¹¹. For the current analysis, the brain was segmented into 463 cortical and subcortical regions of interest³¹. Each surface vertex from the cortical thickness images was mapped to the nearest volumetric parcel (see Methods). To examine the propagation hypothesis, the connectivity ($Conn_{ij}$) between any cortical parcel i and any parcel belonging to the disease reservoir j was measured. Here we calculated $Conn_{ij}$ based on healthy brain connectomes (see Methods). The analysis was performed for the whole brain, and for each hemisphere separately using Spearman’s correlation to examine the relation between disease progression and exposure. Disease exposure was defined as the product of connectivity and atrophy measure in the corresponding disease reservoir region j at the onset of the disease, summed over all possible connections.

$$Disease\ Exposure(i) = \sum_j Conn_{ij} \cdot Atrophy(j)$$

Both functional and structural connectivity were used to test the propagation hypothesis (Figure 5). Connectomes were generated using data from young healthy individuals to calculate the $Conn_{ij}$. Atrophy(j) was set equal to the z-value at each region j of the independent component demonstrating atrophy in PD compared to HC from the previously computed DBM map from the baseline MRI¹¹. Note that for areas not showing significant atrophy at baseline the value of $Atrophy(j)$ is equal to 0.

First, a functional connectome was generated using resting state fMRI to define $Conn_{ij}$.

Significant correlation was observed between regional cortical thinning and disease exposure ($r=0.19$, $p<0.0001$). Significance was confirmed by permutation testing where we kept the connectivity structure (i.e. subcortical-cortical connections) intact and permuted the cortical thinning values ($n=10,000$) and the 95% confidence interval was measured using bootstrapping ($n=10,000$) ($r \in [0.11, 0.28]$, $p_{\text{perm}}<0.0001$). Moreover, cortical thickness of both the left ($r=0.22$, $p=0.0005$, $r \in [0.09, 0.34]$, $p_{\text{perm}}=0.0004$) and right hemisphere ($r=0.27$, $p<0.0001$, $r \in [0.16, 0.38]$, $p_{\text{perm}}<0.0001$) significantly correlated with the disease exposure from bilateral affected regions.

Second, the same hypothesis was tested using structural connectivity as measured by diffusion-weighted MRI (DW-MRI). Though the correlation was not significant at the whole-brain level ($r= -0.03$, $p=0.239$, $r \in [-0.12, 0.06]$, $p_{\text{perm}}=0.762$), change in cortical thickness and disease exposure within the individual hemispheres were significantly correlated. Similar results were observed within the left hemisphere ($r=0.14$, $p=0.016$, $r \in [0.01, 0.27]$, $p_{\text{perm}}=0.016$) and the right hemisphere ($r=0.11$, $p=0.044$, $r \in [-0.02, 0.25]$, $p_{\text{perm}}=0.041$). Failure to capture the relationship at the whole brain level may be due to inherent limitations in DW-MRI to detect interhemispheric connectivity³²⁻³⁶ (See Discussion).

For comparison, when only considering pure Euclidean distance, we found that cortical thickness of neither the whole-brain ($r=-0.06$, $p=0.104$, $r \in [-0.15, 0.03]$, $p_{\text{perm}}=0.105$) nor the left hemisphere ($r=-0.09$, $p=0.088$, $r \in [-0.22, 0.04]$, $p_{\text{perm}}=0.084$) correlated with the disease exposure from bilateral affected regions. However, when only considering the right hemisphere, we observed significant results ($r=-0.21$, $p=0.0007$, $r \in [-0.33, -0.09]$, $p_{\text{perm}}=0.0006$)

We also tested the relative contribution of functional and structural networks to disease spread using a multivariate model for each hemisphere. Within the left hemisphere, the analysis shows that both functional connectivity ($\beta = .18$, $t(220)=-3.88$, $p<0.001$) and structural connectivity ($\beta = .04$, $t(220)=-2.27$, $p=0.02$) significantly relate to cortical atrophy. Within the right hemisphere, again functional connectivity ($\beta = .12$, $t(220)=-2.56$, $p=0.01$) and structural connectivity ($\beta = .08$, $t(220)=-2.77$, $p<0.01$) significantly relate to cortical atrophy. These results suggest that both types of connectivity play a role in the disease spread model, however, functional connectivity appears to be more significant.

Relationship between cortical thinning and cognitive and CSF measures

Additional analyses restricted to the PD group were performed to investigate the relationship between cortical thinning of the four identified clusters and other disease-related measures. To test whether CSF measures may contribute to the cortical thinning within each of the clusters, we conducted partial correlations (controlling for age and gender). We found changes in the left frontal ($r=-0.16$, $p=0.05$) and left occipital cluster ($r=-0.18$, $p=0.037$) both correlated with CSF $\text{A}\beta_{42}$. Changes of the left occipital cluster ($r=0.17$, $p=0.043$) also correlated with CSF α -syn. We then performed a linear regression model to examine whether cortical thinning was related to cognitive decline (as assessed by MoCA) and found the overall model was significant ($r^2=0.12$, $p=0.028$). Further post-hoc analysis revealed that only the cortical thinning of the left frontal cluster ($r=-0.19$, $p=0.03$) significantly related to MoCA changes. Note that these analyses fail to survive correction for multiple comparisons of the 4 significant clusters.

CSF measures did not correlate with individual time-point measures nor changes in MoCA or motor severity as assessed by UPDRS-III (all $p>.05$). No significant correlation was observed

between cortical thickness of any of the four clusters and measures of UPDRS-III or p-tau₁₈₁. In the control group, no significant correlations between cortical thickness and measures of UPDRS-III, MoCA or CSF biomarkers were observed.

DISCUSSION

The present study investigated 105 PD and 57 control participants over a one-year period following initial diagnosis. Early PD progression was associated with significant cortical thinning. While aging was also associated with cortical thinning, PD patients demonstrated significantly greater reduction in cortical thickness than controls (0.028mm vs 0.019mm reduction on average). This was observed mostly in parts of the left occipital and bilateral frontal lobes and right somatomotor-sensory cortex – regions largely belonging to the limbic, frontoparietal, ventral attention and default mode networks.

We tested the theory that neurodegeneration in PD results from a disease spreading process that enters the cerebral cortex from initially affected subcortical areas. Per the network propagation hypothesis, neurodegenerative diseases result from the aggregation and propagation of misfolded proteins, which in turn results in neuronal death and brain atrophy^{2,5}. The distribution of focal cortical thinning should therefore be contingent on connectivity to already affected areas, which we call a “disease reservoir” by analogy to the spread of epidemics in populations. In the present study, we tested this hypothesis in PD with longitudinal data. We found that cortical regions with greater connectivity (measured functionally or structurally) to the subcortical disease reservoir identified at time of diagnosis demonstrated greater cortical atrophy over the one-year period. This is in line with our previous work using DBM in the initial scan from this dataset¹¹, which indicated that regions demonstrating the greatest atrophy were those belonging to a connectivity

network with an epicenter in substantia nigra - the hypothesized origin of misfolded protein spread to the supratentorial cerebrum in PD.

Some aspects of our model deserve mention. Predictions based on physical distance were similar to topographical distance based on DW-MRI in the right hemisphere. This may be a result of the known distance bias of probabilistic tractography³⁴ or that the brain is organized such that neuronal connectivity correlates with Euclidean distance³⁵. Resting state connectivity, however, better predicted atrophy in comparison to both tractography and topographical distance, thus supporting the notion that connectivity improves our measure of propagation above and beyond consideration of geometrical distance alone. Moreover, there is no described mechanism by which a protein spreads physically through the neuropil. While functional connectivity models fit the data at a whole-brain level, we only observed a relationship between connectivity and thinning in individual hemispheres when using a DW-MRI connectome. This is perhaps due to inherent limitations in DW-MRI to capture interhemispheric connections^{33,36}. Mathematical models of the dynamic spread through brain networks, accounting for factors such as protein accumulation and clearance, have been proposed in recent years for Alzheimer's Disease³⁷⁻³⁹. However, further research is needed to extend these models to PD.

Within PD, greater reduction in cortical thickness of the left frontal cluster over the one-year period was associated with worsening cognition (as assessed by the MoCA), although the p value of 0.03 would not survive correction for multiple comparisons. This mirrors results from other studies that have similarly found trending results^{24,40}. While dementia is rare in early PD, especially as our cohort was selected to exclude dementia at baseline, we still see greater cortical thinning of frontal clusters in the PD group one-year post-diagnosis. Cortical neuronal degeneration could be occurring earlier in the clinical course of PD than once thought. Although

PD is primarily thought of as a movement disorder, it is recognized to be a brain-wide neurodegenerative process that spreads up from brainstem into cortex, as originally suggested by Braak⁴¹.

In this dataset only cortical thinning of the left frontal cluster related to cognitive decline. Furthermore, thinning in this frontal cluster was weakly related to reduced A β ₄₂ at baseline (Figure 4). Lower CSF A β ₄₂ and α -syn were also associated with occipital thinning, which did not correlate with cognitive decline. The frontal clusters demonstrating greater loss of cortical thickness in PD involved lateral and medial frontal cortex, predominantly in ventral and orbitofrontal areas. These regions of frontal lobe belong to the limbic system, the frontoparietal systems implicated in focused attention, and the default mode network, implicated in memory retrieval. This pattern of frontal atrophy is similar to that described in a subgroup of AD patients identified by hierarchical clustering⁴², and in patients with behavioral variant frontotemporal dementia¹. A notable difference between the pattern of cortical atrophy described here and that commonly seen in AD is the relative absence of more posterior involvement (precuneus, posterior cingulate and parietal lobe) in our PD cohort. The effect seen here is much more anterior, possibly reflecting the propagation of disease via dopamine projections. Nonetheless, the default mode network is also disrupted in AD^{43,44}, and a target of amyloid plaques⁴⁵. The anterior default mode network may be an avenue through which dementia develops in PD. We note also that, in the Braak model of AD, the initial cortical site of amyloid- β involvement is the ventral frontal cortex⁴⁶, and that the observed ventral frontal atrophy pattern in PD shows a high degree of similarity to early A β ₄₂ deposition measured by positron emission tomography in Alzheimer's Disease⁴⁷.

While cognitive impairment is a recognized consequence of PD²⁵, its underlying mechanism is not well understood. Our findings suggest that, in the PD group, higher A β ₄₂ deposition in the brain at baseline (indicated by lower CSF A β ₄₂ levels⁴⁸) predicted greater cortical thinning of the left frontal cluster over the one-year period. Though our results are not conclusive, they suggest that A β ₄₂ may make the PD brain more susceptible to cortical thinning and in turn, more prone to cognitive decline. Indeed, recent positron emission tomography studies have revealed that cortical amyloid deposits are associated, in a dose-dependent manner, with increased risk for cognitive decline in PD⁴⁹. Additionally, low CSF A β ₄₂ has previously been associated with risk of subsequent dementia in PD⁵⁰. These findings provide evidence in favor of potentially overlapping mechanisms for dementia in PD and AD. Previous research found that 28% of PD patients have AD pathological features at post-mortem⁵¹. While it can be argued that the findings observed in the present study may be driven by coincidental occurrence of Alzheimer's Disease, we found that only 5 of 105 PD subjects met a proposed CSF amyloid-positive criterion⁵². A possible alternate explanation is that synergy between A β ₄₂ and α -syn deposition promotes cognitive impairment in PD⁵³. A β ₄₂ has been found to promote grey matter atrophy in distributed regions of the parietal and frontal lobe in the normal aging brain⁵⁴, akin to the atrophy pattern observed in the present study; α -syn may accelerate the neurodegenerative process associated with normal age-related A β ₄₂ deposition, especially in regions connected to the PD disease reservoir.

The pattern of cortical atrophy in these de novo PD patients may account for the constellation of mood and cognitive deficits that eventually characterize PD dementia. Involvement of the lateral prefrontal cortex and striatum could lead to executive dysfunction. Inferior frontal areas also affected in behavioural variant frontotemporal dementia may be implicated in apathy,

compulsive behaviors, changes in personality, and social deficits. Finally, DMN involvement could account for Alzheimer-like memory deficits while degeneration of ventral visual stream areas could explain visual hallucinations. Using the Neurosynth program and database⁵⁵ we searched for the terms most often associated in fMRI publications with each anatomical cluster demonstrating atrophy in PD (Figure 6). The left occipital-temporal cluster is associated with (visual) motion, observation, perception and vision. The right somatomotor-sensory cluster is associated with movement. The frontal clusters are associated with expressions related to language, and to the terms theory of mind, self, social, mentalizing, and memory. The atrophic regions observed here sub-serve the cognitive functions that fail in PD dementia.

Findings from this study should be considered in light of some limitations. While the cellular events leading to changes in cortical thickness are not clear, cortical thickness as measured with T1-weighted MRI is nonetheless believed to reflect neuronal density along with glial support and dendritic arborization^{56,57}. In PD, reductions in cortical thickness most likely reflect neurodegeneration. In the current paper, we address the “protein spread” model, which we note remains controversial and lacking in supportive human evidence⁷⁻⁹. With our current dataset and imaging modalities, we cannot rule out the possibility of a stochastic attack on the brain as a whole that would give the appearance of network spread. Areas that are connected could share features (e.g., gene expression⁵⁸) that make them similarly vulnerable to a specific pathophysiological process. In this case, the map of atrophy would look like a network but not be driven by connectivity. Additionally, neurodegeneration could propagate due to loss of trophic factors having nothing to do with misfolded protein spread. Moreover, we cannot measure α -syn accumulation, but only its consequence (cortical thinning), and the two may have a complex and non-linear relationship. However, the present finding that a connectivity model explains disease

progression better than chance lends support to the network propagation hypothesis. The inclusion criterion of MoCA>26 may have biased both the PD and HC pool. Also, while our sample is relatively large, the PPMI sample is a research-based cohort and may not be truly representative of a population-based cohort. Finally, most patients were prescribed dopaminergic treatments after diagnosis, which may mask the magnitude of cognitive decline and motor symptoms and their relationship with brain atrophy. Future longitudinal studies and follow-up with patients at later stages of the disease as well as postmortem confirmation are needed to understand the relationship between cortical atrophy and the underlying disease process.

The current study is the largest to date to assess longitudinal measures of cortical thickness using 3T MRI in a *de novo* PD cohort. Our findings suggest that disease propagation to the cortex occurs earlier than previously thought. Focal cortical thinning may be contingent on connectivity to a disease reservoir: the greater the connections, the higher the disease exposure, and the more the cortical atrophy. PD progression involves subcortical α -syn spreading through intrinsic brain networks to the cortex, possibly in synergy with $\text{A}\beta_{42}$, which may be the harbinger of cognitive decline.

METHODS

Eligibility criteria and study procedures have been previously detailed¹⁰. Each participating PPMI site received approval from their local institutional review board, and obtained written informed consent from all subjects. Analysis of this dataset was approved by the Montreal Neurological Institute Research Ethics Board. Only participants with 3T MRI data at both initial

visit and one-year follow-up were included in the present study. Of the 237 PD patients with 3T acquisition at baseline, 122 had MRI data at the one-year follow-up. For controls, 118 subjects had 3T acquisition at baseline, and 62 had MRI data at the one-year follow-up.

All non-categorical data were normally distributed as per Shapiro-Wilk tests. Group difference in sociodemographic and neuropsychological variables were analyzed using the χ^2 test for categorical data, and *t*-test for normally distributed data.

MRI Acquisition

T1-weighted MRI scans were acquired in the sagittal plane on 3T scanners at each study site using a magnetization-prepared rapid-acquisition gradient echo sequence (full study protocol: <http://www.ppmi-info.org/study-design/research-documents-and-sops/>). Acquisition parameters were as follows: repetition time = 2,300/1,900ms; echo time = 2.98/2.96/2.27/2.48/2.52ms; inversion time = 900ms; flip angle: 9°; 256 × 256 matrix; and 1 × 1 × 1 mm³ isotropic voxel. Acquisition site was used as a covariate in all analyses.

Cortical Thickness

Cortical thickness models were generated from the T1-weighted 3T MRI scans using the CIVET2.1 preprocessing pipeline⁵⁹. A summary of the steps involved follows; further details can be found online (<http://www.bic.mni.mcgill.ca/ServicesSoftware/CIVET>). The T1-weighted MRIs were linearly registered to the MNI -ICBM152 volumetric template^{60,61}. Images were then

corrected for signal intensity non-uniformity⁶², and a brain mask was calculated from each input image. Images were then segmented into grey matter, white matter, CSF, and background⁵⁹. After the CIVET pipeline, quality control was carried out by 2 independent reviewers using previously described criteria⁶³ to ensure adequate quality of the T1-weighted volume images, such as linear and nonlinear registration, and to exclude distortions in grey and white matter surfaces, and motion artifacts. 17 of 122 PD and 5 of 62 HC failed quality control.

The distance between corresponding vertices of inner and outer cortical surfaces were evaluated by a fully automated method (Constrained Laplacian Anatomic Segmentation using Proximity algorithm)⁶⁴ to provide a measure of cortical thickness at each vertex. The white and grey matter interface was fitted across 40,692 vertices in each hemisphere to create the inner cortical surface, then expanded to fit the grey matter and CSF interface to create the outer cortical surface. The surfaces of each subject were nonlinearly registered to an average surface created from the volumetric ICBM152 template. In order to test the propagation hypothesis, the brain was segmented into 448 cortical and 15 subcortical regions³¹, and each of the 40,692 cortical vertices from the cortical thickness analysis was interpolated and assigned to one of the 448 cortical parcels.

Changes in cortical thickness were calculated by subtracting the values ($\Delta t = t_2 - t_1$) at the one year follow-up (t_2) from the baseline (t_1) for both groups using the SurfStat software package (<http://www.math.mcgill.ca/keith/surfstat/>). Difference between PD and controls [($PD_1 - PD_2$) - ($HC_1 - HC_2$)] were analyzed statistically based on random field theory with a threshold of $p < .05$ corrected for multiple comparisons over the entire cortical surface⁶⁵.

Observed differences in cortical thickness were then correlated to other potential disease-related measures (i.e., UPDRS-III, MoCA, CSF α -syn, and tau and $A\beta_{42}$ markers) using Pearson partial correlations. Within PD patients, the difference in cognitive performance over the one-year interval was examined using a linear regression model with MoCA as the dependent variable and the thinning of the four cortical clusters as independent variables. To test whether cortical thickness of a specific cluster was linked to cognitive performance, post-hoc analyses using partial correlations were conducted. Age at baseline and gender were used as confounding covariates for all analyses including for partial correlations, linear regression model, and for obtaining cortical thickness.

Deformation Based Morphometry and Independent Component Analysis

Data were analyzed from the baseline visits of newly diagnosed PD patients ($n = 232$) and an age-matched control group ($n = 117$) obtained from the PPMI database. All subjects' initial visit 3T high-resolution T1-weighted MRI scans underwent preprocessing steps including denoising⁶⁶, intensity non-uniformity correction⁶², and intensity range normalization. Next, each subject's T1-weighted image was first linearly, and then nonlinearly, registered to the MNI-ICBM152 template. Using the resulting non-linear transformation fields, we calculated deformation morphometry maps (i.e. the determinant of the Jacobian matrix of transformation). DBM maps were then concatenated and independent component analysis (ICA) was employed to define independent sources of deformation in the brain. For the resulting ICA components ($n=30$), the PD group was compared to healthy controls (unpaired t-test). The atrophy level significantly differed between PD and control groups in only one of these components after correcting for

multiple comparisons (Bonferroni correction) suggesting this component captures PD-specific alterations in the brain. We used this component (referred to as PD-ICA here) as our atrophy map. The component score (atrophy measure) in PD-ICA for each subject was significantly correlated with disease severity as measured by UPDRS-III and SBR. Please see Zeighami et al.¹¹ for details.

Connectivity and Disease Propagation

The difference in cortical thinning in PD versus controls was used to define disease progression. DBM on the baseline MRI was employed to assess disease-related brain atrophy and to define a source, or reservoir, for disease propagation. As previously, based on a parcellation that is a subdivision of the common FreeSurfer implementation of the Desikan-Killiany Atlas, grey matter was segmented into 463 regions of interest of approximately similar size. Of these parcels, 448 were cortical and 15 were subcortical (thalamus, caudate, putamen, pallidum, accumbens, hippocampus, amygdala in each hemisphere and brainstem)³¹. Each surface vertex from the cortical thickness analysis was then mapped to the corresponding nearest whole-brain parcel from the Atlas. The “disease reservoir” was defined as the 15 subcortical parcels from the Atlas, and the Atrophy value at each parcel was obtained from the DBM map.

To generate brain networks and connectomes, data-driven brain parcellations from young healthy individuals were used³¹. The functional connectivity map was derived from resting state fMRI data of 40 young healthy subjects (25.3 ± 4.9 yr old, 24 males)⁶⁷. The scans were done using Siemens Medical Trio 3T MRI scanner, consisting of a high resolution T1-weighted image, as

well as T2*-weighted images with BOLD contrast (3.3 mm isotropic voxels, TR 1920 ms, 280 time-frames). The dataset was pre-processed using conventional steps consisting of rigid body motion correction, correcting for nuisance variables (white matter, cerebrospinal fluid, motion parameters), and low pass filtering. The structural connectivity map was generated using the Illinois Institute of Technology Human Brain Atlas v.3, (freely available at <http://www.iit.edu/~mri/Home.html>). The atlas was constructed using data from 72 neurologically healthy subjects (20-40 yr old, 28.8 ± 5.5 yr old, 30 males). All subjects were scanned using a 3T General Electric MRI scanner (GE, Waukesha, WI) with the following parameters (TR = 5800ms, TE = 94ms, voxel size = 3 mm³, 256×256 final image matrix, FoV = 24 × 24cm, b = 900s/mm², 45 slices for 12 diffusion directions uniformly distributed in 3D space, scan-time: 21 min 57s)⁶⁸. Imposing a maximum of 500-mm trace length and a curvature threshold of ± 90 , the anatomical connection probability (ACP) was calculated between all pairs of regions using a probabilistic graph-based tractography algorithm⁶⁹.

Spearman's correlation was used to investigate the relationship between disease progression in cortical areas (cortical thinning) and the 'disease exposure' for each region in the PD-ICA (defined by the average values of each region weighted by connectivity). The same procedure was performed to test propagation hypotheses along the functional and structural connectomes. The propagation analysis was performed for the whole brain and for each hemisphere separately.

CSF Measures

CSF A β ₄₂, α -syn, t-tau, and p-tau₁₈₁ from aliquots were assessed as previously described^{70,71}. The MAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research use-only reagents) immunoassays was used for A β ₄₂, t-tau and p-

tau₁₈₁. CSF α-syn assay was performed at Covance using a commercially available ELISA assay kit (Covance, Dedham, MA)⁷². To evaluate the possible contamination of blood in CSF – a factor thought to influence the level of some proteins including α-syn and Aβ₄₂^{73,74} – the relationship between CSF hemoglobin and other CSF measures was assessed. No significant association was observed (all $p < 0.05$), suggesting that there is no effect of added blood on concentration of CSF measures. Due to the ongoing nature of the study and incomplete data, only CSF data from baseline was used in this analysis⁷².

Data Availability

The DBM maps are available at <https://neurovault.org/collections/860/>. Cortical thickness maps will be made available on request. The CIVET pipeline is available at <http://www.bic.mni.mcgill.ca/ServicesSoftware/CIVET>. The functional and structural connectome data are from cited sources and available upon request from the authors of the related publications.

Code Availability

All code written by the authors of this manuscript is available upon request.

Acknowledgements

PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Teva, and UCB.

Research supported by grants from the Michael J Fox Foundation for Parkinson's Research, the W. Garfield Weston Foundation, and the Alzheimer's Association, the Canadian Institutes of Health Research, and the Natural Sciences and Engineering Research Council of Canada to A. Dagher. Y. Yau is a Vanier Scholar and receives funding from the Canadian Institute of Health Research. Y. Zeighami holds the Jeanne Timmins Costello Fellowship.

Author Contributions

YY, YZ and AD contributed to the study design and interpretation. YY, YZ, TB, KL, UV, and MD analyzed the data. VF, BM, DLC, PH and AG contributed methods. YY drafted the initial manuscript; all authors contributed to writing of this manuscript.

Competing Financial Interests

None.

References

- 1 Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D. Neurodegenerative diseases target large-scale human brain networks. *Neuron* 62, 42-52, doi:10.1016/j.neuron.2009.03.024 (2009).
- 2 Warren, J. D. *et al.* Molecular nexopathies: a new paradigm of neurodegenerative disease. *Trends in neurosciences* 36, 561-569, doi:10.1016/j.tins.2013.06.007 (2013).
- 3 Burre, J. *et al.* Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science (New York, N.Y.)* 329, 1663-1667, doi:10.1126/science.1195227 (2010).
- 4 Olanow, C. W. & Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? *Mov Disord* 28, 31-40, doi:10.1002/mds.25373 (2013).
- 5 Luk, K. C. *et al.* Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science (New York, N.Y.)* 338, 949-953, doi:10.1126/science.1227157 (2012).
- 6 Braak, H. *et al.* Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of Aging* 24, 197-211, doi:[http://dx.doi.org/10.1016/S0197-4580\(02\)00065-9](http://dx.doi.org/10.1016/S0197-4580(02)00065-9) (2003).
- 7 Walsh, D. M. & Selkoe, D. J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. *Nat Rev Neurosci* 17, 251-260, doi:10.1038/nrn.2016.13 (2016).
- 8 Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. *Nat Rev Neurosci* 18, 101-113, doi:10.1038/nrn.2016.178 (2017).
- 9 Engelender, S. & Isacson, O. The Threshold Theory for Parkinson's Disease. *Trends in neurosciences* 40, 4-14, doi:10.1016/j.tins.2016.10.008 (2017).

- 10 Marek, K. *et al.* The Parkinson Progression Marker Initiative (PPMI). *Progress in Neurobiology* 95, 629-635, doi:<http://dx.doi.org/10.1016/j.pneurobio.2011.09.005> (2011).
- 11 Zeighami, Y. *et al.* Network structure of brain atrophy in de novo Parkinson's disease. *eLife* 4, e08440, doi:[10.7554/eLife.08440](https://doi.org/10.7554/eLife.08440) (2015).
- 12 Reetz, K. *et al.* Structural imaging in the presymptomatic stage of genetically determined parkinsonism. *Neurobiology of disease* 39, 402-408, doi:[10.1016/j.nbd.2010.05.006](https://doi.org/10.1016/j.nbd.2010.05.006) (2010).
- 13 Fioravanti, V. *et al.* MRI Correlates of Parkinson's Disease Progression: A Voxel Based Morphometry Study. *Parkinson's Disease* 2015, 8, doi:[10.1155/2015/378032](https://doi.org/10.1155/2015/378032) (2015).
- 14 Camicioli, R. *et al.* Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. *Parkinsonism & Related Disorders* 15, 187-195, doi:<http://dx.doi.org/10.1016/j.parkreldis.2008.05.002> (2009).
- 15 Menke, R. A. *et al.* Comprehensive morphometry of subcortical grey matter structures in early-stage Parkinson's disease. *Human brain mapping* 35, 1681-1690 (2014).
- 16 Davatzikos, C. Why voxel-based morphometric analysis should be used with great caution when characterizing group differences. *NeuroImage* 23, 17-20, doi:<http://dx.doi.org/10.1016/j.neuroimage.2004.05.010> (2004).
- 17 Hutton, C., Draganski, B., Ashburner, J. & Weiskopf, N. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. *Neuroimage* 48, 371-380, doi:[10.1016/j.neuroimage.2009.06.043](https://doi.org/10.1016/j.neuroimage.2009.06.043) (2009).

18 Pereira, J. B. *et al.* Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. *Hum Brain Mapp* 33, 2521-2534, doi:10.1002/hbm.21378 (2012).

19 Khundrakpam, B. S., Lewis, J. D., Kostopoulos, P., Carbonell, F. & Evans, A. C. Cortical Thickness Abnormalities in Autism Spectrum Disorders Through Late Childhood, Adolescence, and Adulthood: A Large-Scale MRI Study. *Cerebral Cortex* 27, 1721-1731 (2017).

20 Dickerson, B. C. *et al.* The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. *Cerebral cortex (New York, N.Y. : 1991)* 19, 497-510, doi:10.1093/cercor/bhn113 (2009).

21 Ibarretxe-Bilbao, N. *et al.* Progression of cortical thinning in early Parkinson's disease. *Mov Disord* 27, 1746-1753, doi:10.1002/mds.25240 (2012).

22 Jubault, T. *et al.* Patterns of cortical thickness and surface area in early Parkinson's disease. *Neuroimage* 55, 462-467, doi:10.1016/j.neuroimage.2010.12.043 (2011).

23 Zarei, M. *et al.* Cortical thinning is associated with disease stages and dementia in Parkinson's disease. *Journal of Neurology, Neurosurgery, and Psychiatry* 84, 875-882, doi:10.1136/jnnp-2012-304126 (2013).

24 Pereira, J. B. *et al.* Initial cognitive decline is associated with cortical thinning in early Parkinson disease. *Neurology* 82, 2017-2025, doi:10.1212/wnl.0000000000000483 (2014).

25 Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov Disord* 23, 837-844, doi:10.1002/mds.21956 (2008).

26 Aarsland, D. *et al.* Cognitive decline in Parkinson disease. *Nat Rev Neurol* 13, 217-231, doi:10.1038/nrneurol.2017.27 (2017).

27 Dirnberger, G. & Jahanshahi, M. Executive dysfunction in Parkinson's disease: a review. *J Neuropsychol* 7, 193-224, doi:10.1111/jnp.12028 (2013).

28 Callesen, M. B., Weintraub, D., Damholdt, M. F. & Moller, A. Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. *Parkinsonism Relat Disord* 20, 22-26, doi:10.1016/j.parkreldis.2013.09.006 (2014).

29 Ffytche, D. H. *et al.* The psychosis spectrum in Parkinson disease. *Nat Rev Neurol* 13, 81-95, doi:10.1038/nrneurol.2016.200 (2017).

30 Yeo, B. T. *et al.* The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *Journal of neurophysiology* 106, 1125-1165 (2011).

31 Cammoun, L. *et al.* Mapping the human connectome at multiple scales with diffusion spectrum MRI. *Journal of Neuroscience Methods* 203, 386-397, doi:<http://dx.doi.org/10.1016/j.jneumeth.2011.09.031> (2012).

32 Neher, P. F., Descoteaux, M., Houde, J.-C., Stieltjes, B. & Maier-Hein, K. H. Strengths and weaknesses of state of the art fiber tractography pipelines – A comprehensive in-vivo and phantom evaluation study using Tractometer. *Medical Image Analysis* 26, 287-305, doi:<http://dx.doi.org/10.1016/j.media.2015.10.011> (2015).

33 Thomas, C. *et al.* Anatomical accuracy of brain connections derived from diffusion MRI tractography is inherently limited. *Proceedings of the National Academy of Sciences of the United States of America* 111, 16574-16579, doi:10.1073/pnas.1405672111 (2014).

34 Jbabdi, S., Sotropoulos, S. N., Haber, S. N., Van Essen, D. C. & Behrens, T. E. Measuring macroscopic brain connections in vivo. *Nat Neurosci* 18, 1546-1555, doi:10.1038/nn.4134 (2015).

35 Ercsey-Ravasz, M. *et al.* A Predictive Network Model of Cerebral Cortical Connectivity Based on a Distance Rule. *Neuron* 80, 184-197, doi:<http://dx.doi.org/10.1016/j.neuron.2013.07.036> (2013).

36 Jones, D. K., Knosche, T. R. & Turner, R. White matter integrity, fiber count, and other fallacies: the do's and don'ts of diffusion MRI. *Neuroimage* 73, 239-254, doi:10.1016/j.neuroimage.2012.06.081 (2013).

37 Raj, A., Kuceyeski, A. & Weiner, M. A network diffusion model of disease progression in dementia. *Neuron* 73, 1204-1215, doi:10.1016/j.neuron.2011.12.040 (2012).

38 Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C. & and the Alzheimer's Disease Neuroimaging, I. Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. *PLOS Computational Biology* 10, e1003956, doi:10.1371/journal.pcbi.1003956 (2014).

39 Zhou, J., Gennatas, E. D., Kramer, J. H., Miller, B. L. & Seeley, W. W. Predicting regional neurodegeneration from the healthy brain functional connectome. *Neuron* 73, 1216-1227, doi:10.1016/j.neuron.2012.03.004 (2012).

40 Caspell-Garcia, C. *et al.* Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. *PLOS ONE* 12, e0175674, doi:10.1371/journal.pone.0175674 (2017).

41 Braak, H. & Braak, E. Pathoanatomy of Parkinson's disease. *Journal of Neurology* 247, II3-II10, doi:10.1007/pl00007758 (2000).

42 Hwang, J. *et al.* Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 2, 58-67, doi:<http://dx.doi.org/10.1016/j.dadm.2015.11.008> (2016).

43 Greicius, M. D., Srivastava, G., Reiss, A. L. & Menon, V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. *Proceedings of the National Academy of Sciences of the United States of America* 101, 4637-4642, doi:[10.1073/pnas.0308627101](https://doi.org/10.1073/pnas.0308627101) (2004).

44 Koch, W. *et al.* Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease. *Neurobiology of Aging* 33, 466-478, doi:<http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.013> (2012).

45 Sheline, Y. I. *et al.* Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly. *Biological Psychiatry* 67, 584-587, doi:<http://dx.doi.org/10.1016/j.biopsych.2009.08.024> (2010).

46 Braak, H. & Braak, E. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories. *Neurobiology of Aging* 18, 351-357, doi:[http://doi.org/10.1016/S0197-4580\(97\)00056-0](http://doi.org/10.1016/S0197-4580(97)00056-0) (1997).

47 Villain, N. *et al.* Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. *Brain* 135, 2126-2139, doi:[10.1093/brain/aws125](https://doi.org/10.1093/brain/aws125) (2012).

48 Palmqvist, S. *et al.* Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA neurology* 71, 1282-1289, doi:[10.1001/jamaneurol.2014.1358](https://doi.org/10.1001/jamaneurol.2014.1358) (2014).

49 Gomperts, S. N. *et al.* PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. *Neuro-degenerative diseases* 16, 118-124, doi:10.1159/000441421 (2016).

50 Alves, G. *et al.* CSF A β 42 predicts early-onset dementia in Parkinson disease. *Neurology* 82, 1784-1790, doi:10.1212/WNL.000000000000425 (2014).

51 Irwin, D. J. *et al.* Neuropathologic substrates of Parkinson disease dementia. *Annals of neurology* 72, 587-598, doi:10.1002/ana.23659 (2012).

52 McMillan, C. T. & Wolk, D. A. Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry* 87, 1112-1122, doi:10.1136/jnnp-2015-312690 (2016).

53 Frey, K. A. & Petrou, M. Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. *Clinical and translational imaging* 3, 57-64, doi:10.1007/s40336-015-0104-4 (2015).

54 Sepulcre, J. *et al.* In vivo tau, amyloid, and gray matter profiles in the aging brain. *Journal of Neuroscience* 36, 7364-7374 (2016).

55 Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C. & Wager, T. D. Large-scale automated synthesis of human functional neuroimaging data. *Nature methods* 8, 665-670 (2011).

56 Chklovskii, D. B., Mel, B. & Svoboda, K. Cortical rewiring and information storage. *Nature* 431, 782-788 (2004).

57 la Fougère, C. *et al.* Where in-vivo imaging meets cytoarchitectonics: The relationship between cortical thickness and neuronal density measured with high-resolution

[18F]flumazenil-PET. *NeuroImage* 56, 951-960, doi:<http://dx.doi.org/10.1016/j.neuroimage.2010.11.015> (2011).

58 Richiardi, J. *et al.* Correlated gene expression supports synchronous activity in brain networks. *Science (New York, N.Y.)* 348, 1241-1244, doi:10.1126/science.1255905 (2015).

59 Ad-Dab'bagh, Y. *et al.* The CIVET image-processing environment: a fully automated comprehensive pipeline for anatomical neuroimaging research. *Proceedings of Organization for Human Brain Mapping* (2006).

60 Fonov, V. S., Evans, A. C., McKinstry, R. C., Almlie, C. & Collins, D. Unbiased nonlinear average age-appropriate brain templates from birth to adulthood. *NeuroImage* 47, S102 (2009).

61 Fonov, V. *et al.* Unbiased average age-appropriate atlases for pediatric studies. *NeuroImage* 54, 313-327, doi:<http://dx.doi.org/10.1016/j.neuroimage.2010.07.033> (2011).

62 Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE transactions on medical imaging* 17, 87-97, doi:10.1109/42.668698 (1998).

63 Simmons, A. *et al.* The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. *International journal of geriatric psychiatry* 26, 75-82 (2011).

64 Kim, J. S. *et al.* Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. *Neuroimage* 27, 210-221, doi:10.1016/j.neuroimage.2005.03.036 (2005).

65 Worsley, K. J. *et al.* A unified statistical approach for determining significant signals in images of cerebral activation. *Human brain mapping* 4, 58-73 (1996).

66 Coupé, P. *et al.* An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. *IEEE transactions on medical imaging* 27, 425-441 (2008).

67 Mišić, B. *et al.* Cooperative and Competitive Spreading Dynamics on the Human Connectome. *Neuron* 86, 1518-1529, doi:10.1016/j.neuron.2015.05.035 (2015).

68 Varentsova, A., Zhang, S. & Arfanakis, K. Development of a High Angular Resolution Diffusion Imaging Human Brain Template. *NeuroImage* 91, 177-186, doi:10.1016/j.neuroimage.2014.01.009 (2014).

69 Iturria-Medina, Y. *et al.* Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. *NeuroImage* 36, 645-660, doi:<https://doi.org/10.1016/j.neuroimage.2007.02.012> (2007).

70 Kang, J., Irwin, D. J., Chen-Plotkin, A. S. & et al. Association of cerebrospinal fluid β -amyloid 1-42, t-tau, p-tau181, and α -synuclein levels with clinical features of drug-naive patients with early parkinson disease. *JAMA neurology* 70, 1277-1287, doi:10.1001/jamaneurol.2013.3861 (2013).

71 Toledo, J. B. *et al.* α -Synuclein improves diagnostic and prognostic performance of tau and A β in Alzheimer's disease. *Acta neuropathologica* 126, 10.1007/s00401-00013-01148-z, doi:10.1007/s00401-013-1148-z (2013).

72 Mollenhauer, B. *et al.* Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. *Neurosci Lett* 532, 44-48, doi:10.1016/j.neulet.2012.11.004 (2013).

73 Bjerke, M. *et al.* Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. *International Journal of Alzheimer's Disease* 2010, 986310, doi:10.4061/2010/986310 (2010).

74 Hong, Z. *et al.* DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain* 133, 713-726 (2010).

Table 1. Demographics, and clinical and neuropsychological measures. t_1 : measures at entry. t_2 : measures at one-year follow-up.

	PD patients	Healthy Controls	<i>t</i> -test/ χ^2	<i>p</i> -value
Age				
t_1	61.06 \pm 9.37	59.05 \pm 10.96	1.224	.223
t_2	62.11 \pm 9.37	60.10 \pm 10.96	1.223	.223
Sex	33F:72M	22F:35M	0.846	.358
UPDRS-III				
t_1	21.67 \pm 9.61	----	----	----
t_2	23.10 \pm 10.67	----	----	----
MoCA				
t_1	27.49 \pm 2.11	28.30 \pm 1.13	-3.162	.002*
t_2	26.67 \pm 2.78	27.35 \pm 2.01	-1.778	.077
α-syn				
t_1	1841.54 \pm 729.73	1898.84 \pm 753.12	-0.462	.645
Aβ42				
t_1	370.33 \pm 97.02	373.36 \pm 92.53	-0.189	.850
t-tau				
t_1	44.77 \pm 18.36	46.06 \pm 19.69	-0.407	.684
p-tau181				
t_1	15.85 \pm 9.74	17.30 \pm 9.84	-0.885	.377

values are expressed as mean \pm standard deviation; * = p < .01; t_1 = baseline; t_2 = one-year follow-up

Figure 1. Changes in cortical thickness in PD patients compared to healthy controls over the one-year study period. Left panel: *t*-statistic comparing PD to HC at baseline and follow-up, at each cortical vertex. Right panel: thresholded map showing areas of significant difference. Cluster corrected *p*-value in blue.




Figure 2. Differences in cortical thickness between PD and HC over one-year. Four peak clusters of cortical thinning in PD were identified in parts of (1) left occipital lobe ($n_{verts}=1081$ [5.53 resels], $p<.0001$), (2) left frontal lobe ($n_{verts}=2115$ [10.99 resels], $p<.0001$), (3) right frontal lobe ($n_{verts}=3720$ [15.79 resels], $p<.0001$), and (4) right somatomotor cortex ($n_{verts}=1990$ [16.56 resels], $p<.0001$). n_{verts} : number of vertices in the significant area.




Figure 3. Cortical thinning in PD vs HC in the seven intrinsic brain networks of Yeo et al²⁷. All seven intrinsic brain networks demonstrated significant cortical thinning with ($p < .0001$ permutation test $n=10,000$): *Visual network* ($\mu = 0.63$; 95% CI $\in [0.46, 0.81]$), *Somamotor network* ($\mu = 0.53$; 95% CI $\in [0.37, 0.69]$), *Dorsal Attention network* ($\mu = 0.52$; 95% CI $\in [0.32, 0.73]$), *Ventral Attention network* ($\mu = 0.86$; 95% CI $\in [0.67, 1.94]$), *Limbic network* ($\mu = 1.2$; 95% CI $\in [0.98, 1.40]$), *Frontoparietal network* ($\mu = 1.05$; 95% CI $\in [0.80, 1.28]$), and *Default Mode network* ($\mu = 0.73$; 95% CI $\in [0.57, 0.88]$). + outliers within each network.




Figure 4. (a) Linear regression model between changes (delta) in cortical thickness clusters and delta cognitive score (MoCA). The overall model was significant; specifically, thinning of the left frontal cluster was significantly related to decline in cognitive performance. (b) Partial correlations of $A\beta_{42}$ with each cortical thickness clusters revealed significant correlations with cortical thinning in the left hemispheric clusters. All analyses controlled for age and gender.




Figure 5. (a) Schematic of the propagation model. The model used a disease reservoir (colored regions) consisting of 15 subcortical regions of interest and connectivity from each region to the cortical surface. (b) PD-specific atrophy map used to define disease “content” in each region of interest of the disease reservoir, derived from deformation based morphometry analysis of patients at baseline (Zeighami et al. 2015). (c-e) Correlation between cortical thinning (average t -values, PD-HC, t_2-t_1) of each cortical region and disease exposure (see text for detail). Connectivity based on functional resting state data in the (c) left and (d) right hemisphere as well as connectivity based on structural diffusion-weighted data in the (e) left and (f) right hemisphere are depicted.




Figure 6. Peaks within each cluster were associated with expressions used in publications using Neurosynth. The x-axes represent correlation values between the cluster and each concept's meta-analytic map generated using seed-based networks. The y-axes represent the most highly correlated concepts per cluster.

